Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.344 EUR | -0.60% | -5.50% | -39.54% |
May. 28 | Solaria expects energy prices to rise this year | RE |
May. 27 | Solaria sees higher energy prices later this year, shares rise | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.92 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.54% | 6.15B | A- | ||
-2.60% | 90.28B | A- | ||
-1.97% | 39.5B | A- | ||
-15.47% | 31.71B | B- | ||
+61.28% | 26.41B | A | ||
-22.81% | 14.34B | C | ||
-8.82% | 12.89B | B- | ||
-11.77% | 11.8B | D+ | ||
-45.97% | 10.95B | B | ||
+3.30% | 8.85B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GRF Stock
- Ratings Grifols, S.A.